Presbyopia is the world's number one cause of vision loss with more than 1 billion individuals affected globally. The total global costs associated with correcting near vision impairment due to uncorrected presbyopia have been estimated at $30.8 billion for a comprehensive eye care model. Both cost to the patient and cost to society, which is greater in low-income countries relative to high-income areas, should be considered. Ultimately, surgical correction of the nonaccommodating dysfunctional natural lens may provide the "cure" for presbyopia. Presbyopia-correcting intraocular lenses (IOLs) may provide better visual acuity and fewer adverse effects. Patients are pursuing cataract surgery at a younger and younger age. Although this expands the viable pool for lens exchange, this younger group of patients has extreme demands and has a much more scrutinizing frame of reference for comparison (a milder cataract). Thus, they are at a much higher risk for dissatisfaction and have a much higher chance of noticing potential adverse effects from multifocal IOLs. Setting appropriate expectations and thoroughly educating patients preoperatively helps create a partnership with the patient and a strong foundation for a successful surgical outcome. A cure for presbyopia has always been considered the holy grail of ophthalmology. In 2021, ophthalmologists are moving closer to achieving this goal while also creating a safer, more productive, cost-effective solution to presbyopia on an individual and on a global level. .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3928/1081597X-20210408-03 | DOI Listing |
J Cardiovasc Surg (Torino)
February 2025
Department of Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium.
Background: Due to the heterogeneity of literature findings, stent type selection for the endovascular treatment of complex aorto-iliac occlusive disease remains challenging. The BELSTREAM study, a physician-initiated, prospective, multicenter, single-arm study, aims to report the safety and efficacy of the balloon expandable LifeStream Peripheral Stent Graft System (BD, Tempe, Arizona, USA) for the treatment of complex TASC C and D aorto-iliac artery lesions.
Methods: Seventy patients and 133 lesions were included at six Belgian institutions.
J Cardiovasc Surg (Torino)
February 2025
Department of Vascular Surgery, ASST Settelaghi Universitary Teaching Hospital, University of Insubria, Varese, Italy.
Optimizing the longevity of vascular access in hemodialysis patients remains a critical aspect of patient care, given the significant role of arteriovenous fistulas (AVFs) and arteriovenous grafts (AVGs) in enabling effective dialysis. Vascular access complications, such as stenosis, thrombosis, and cannulation-related damage, continue to challenge both the functionality and the sustainability of these access points. Recent advancements underscore the importance of a robust follow-up strategy, integrating clinical evaluations with diagnostic tools like color Doppler ultrasound (CDU) and emerging interventional approaches such as drug-coated balloon (DCB) angioplasty.
View Article and Find Full Text PDFEur J Pain
March 2025
Universidad del Bosque, Bogotá, Colombia.
Background: Poor acute postoperative pain control, coupled with the use of intravenous medications with a limited and unsafety efficacy spectrum, has led to new therapeutic alternative explorations to reduce adverse events while increasing its analgesic efficacy. There cannabinoids have been proposed as a useful control agent in post-surgical pain. Nevertheless, to date, there is no solid evidence to evaluate them.
View Article and Find Full Text PDFJ Int Med Res
January 2025
Colombo South Teaching Hospital, Colombo, Sri Lanka.
A 70-year-old man developed intermittent fever with chills, severe anorexia, generalized weakness, and mild exertional difficulty in breathing following posterior chamber intraocular lens replacement surgery for a mature white cataract in the left eye. Laboratory tests revealed persistent negative blood cultures, normocytic and normochromic anemia, neutrophilia, and elevated inflammatory markers despite multiple courses of antibiotics. All other investigations conducted to identify the cause of prolonged fever, including transthoracic echocardiography, were negative.
View Article and Find Full Text PDFCOPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!